This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.

Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Stocks across Asia lost ground on Monday as worries about Chinese AI company DeepSeek reverberated. The company's discounted R1 model knocked tech stocks, sending the Nikkei ( ^N225) in Japan 0.9% ...

Shares in the chipmaker were lower in pre-market trading, after closing Friday’s session with a 3% drop, following the launch ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...

London stocks were set to fall at the open on Monday following a mostly weaker Asian session. The FTSE 100 was called to open ...

Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

Shares of GSK PLC GSK inched down 0.51% to £13.57 Friday, on what proved to be an all-around poor trading session for the ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.